{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:57:32Z","timestamp":1790935052808,"version":"4.1.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Viral hepatitis is a serious yet manageable and preventable public health menace that infects about 3 million of people and leads to 1.1 million deaths worldwide every year. An acute episode of viral hepatitis usually subsides on its own, however, if not intervened timely, chronic infection puts people at risk of cirrhosis, liver cancer, and eventually death. In 2015, the global community allied to tackle viral hepatitis, as a result of which combating viral hepatitis target was included in the sustainable development goals (SDGs), and the World Health Organisation (WHO) constituted the first-ever global health sector strategy on viral hepatitis for 2016 to 2021 which is also renewed recently. Conforming to the global commitment, India launched the National Viral Hepatitis Control Program in the year 2018 with the aim to eliminate viral hepatitis as a public health threat by the year 2030. In the Subsequent years, WHO and various other international societies have released updated recommendations with respect to vaccination, prevention of mother-to-child transmission, strategies to increase testing uptake including self-testing, newer diagnostics including point of care and reflex testing approaches, simplified treatment algorithms, expanded treatment eligibility criteria, and simplified service delivery models. With the program being in its fifth year of implementation, there is a need to revamp the operational guidelines based on various global evidence-based advancements in order to attain the ambitious elimination goal by 2030.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1455_23","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:00:48Z","timestamp":1695967248000},"page":"1755-1758","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["National viral hepatitis control program in India: Call for update"],"prefix":"10.4103","volume":"12","author":[{"given":"Pragya","family":"Pandey","sequence":"first","affiliation":[{"name":"Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Gastrosciences and Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet Singh","family":"Bhadoria","sequence":"additional","affiliation":[{"name":"Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MPG.0000000000001968","article-title":"Dual sofosbuvir\/daclatasvir therapy in adolescent patients with chronic hepatitis C infection","volume":"67","author":"Yakoot","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jvh.13032","article-title":"Safety and efficacy of combined sofosbuvir\/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4","volume":"26","author":"Abdel Ghaffar","year":"2019","journal-title":"J Viral Hepat"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic HCV:Part 2 of the DORA study","volume":"74","author":"Jonas","year":"2021","journal-title":"Hepatology"},{"key":"R7-20260204","article-title":"Direct-acting antivirals for children with chronic hepatitis C:A Brazilian single center experience","author":"Hirsch","year":"2020","journal-title":"ESPID Meeting 2020:European Society for Paediatric Infectious Diseases"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/S2352-3018(23)00029-2","article-title":"Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants:a systematic review of modelling studies","volume":"10","author":"le Roux","year":"2023","journal-title":"Lancet HIV"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"ofaa196","DOI":"10.1093\/ofid\/ofaa196","article-title":"Assessing molecular point-of-care testing and dried blood spot for hepatitis C virus screening in people who inject drugs","volume":"7","author":"Chevaliez","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update:American Association for the Study of Liver Diseases \u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R16-20260204","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-017-2775-0","article-title":"The future of viral hepatitis testing:Innovations in testing technologies and approaches","volume":"17","author":"Peeling","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R23-20260204","first-page":"1553","article-title":"Interpretation of guidelines for the prevention and treatment of chronic hepatitis B (2022 edition)","volume":"39","author":"Yandi","year":"2023","journal-title":"J Clin Hepatol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1455_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:26:50Z","timestamp":1786735610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1455_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1455_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}